FTREHealthcare · BiotechnologyThe 12 Wall Street analysts covering Fortrea Holdings, Inc. hold a median 12-month price target of $20 — +5.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Fortrea Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (9): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Fortrea Holdings, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on FTRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Barclays | Maintains | Equal-Weight | $18 → $22 |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | $20 → $25 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $19 → $26 |
| 13 July 2026 | Mizuho | Maintains | Neutral | $13 → $16 |
| 24 June 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 May 2026 | Mizuho | Maintains | Neutral | — |
| 6 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | Citigroup | Maintains | Buy | — |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 9 Mar 2026 | TD Cowen | Upgrade | Buy | — |
| 27 Feb 2026 | Baird | Maintains | Outperform | — |
| 27 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 22 Jan 2026 | TD Cowen | Maintains | Hold | — |
| 8 Jan 2026 | Truist Securities | Upgrade | Buy | — |
| 6 Jan 2026 | Evercore ISI Group | Upgrade | Outperform | — |
| 18 Dec 2025 | Mizuho | Maintains | Neutral | — |
| 15 Dec 2025 | Barclays | Upgrade | Equal-Weight | — |
| 11 Dec 2025 | Citigroup | Upgrade | Buy | — |
| 6 Nov 2025 | Barclays | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 78% of US stocks
Cheaper than 30% of US stocks
Cheaper than 10% of US stocks
Higher than 22% of US stocks
Higher than 23% of US stocks
Higher than 52% of US stocks
Higher than 26% of US stocks
Higher than 33% of US stocks
Higher than 46% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FTRE appears on the weeks it earns a place.
Fortrea Holdings Inc. (FTRE) was upgraded to a Zacks Rank #1 (Strong Buy) by Zacks Investment Research, reflecting growing optimism about its earnings prospects.
Why it matters — A FTRE watcher would care because an upgrade to Strong Buy from a major research firm signals increased positive sentiment around the company's earnings outlook.
Zacks Investment Research published a comparison between Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX), examining which of the two stocks is the better value option for investors in the Medical - Biomedical and Genetics sector.
Why it matters — FTRE watchers would care because the article evaluates whether FTRE represents an undervalued opportunity relative to ARGX.
FTRE was included in the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026, alongside ASML and KLAC.
Why it matters — Inclusion on this list signals that FTRE is recognized as having strong momentum by Zacks Investment Research's ranking system.
Zacks Investment Research highlighted Fortrea Holdings Inc. (FTRE) as a stock that has shown strong recent momentum while still trading at reasonable prices, passing their "Fast-Paced Momentum at a Bargain" screen.
Why it matters — The report suggests FTRE may be attractively valued despite its recent price momentum, which could be relevant for investors monitoring the stock's growth potential relative to its valuation.
Fortrea Holdings Inc. held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha.
Why it matters — An FTRE watcher would care because the earnings call transcript provides direct details on the company's Q2 2026 financial performance and management commentary.
The 12 Wall Street analysts covering Fortrea Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $13 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Fortrea Holdings, Inc., 5 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Fortrea Holdings, Inc. 97 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Fortrea Holdings, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +5.6% from the last close, and Ticker Nerd's factor model ranks Fortrea Holdings, Inc. 97 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Fortrea Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $26 over the next 12 months.
Fortrea Holdings, Inc. returned +246.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Fortrea Holdings Inc. is a global contract research organization (CRO) providing comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide.
The most recent item we track (Zacks Investment Research, 31 July 2026): "Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know". Fortrea Holdings Inc. (FTRE) was upgraded to a Zacks Rank #1 (Strong Buy) by Zacks Investment Research, reflecting growing optimism about its earnings prospects.
Fortrea Holdings Inc. is a global contract research organization (CRO) providing comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide. It specializes in Phase I through IV clinical trial management, clinical pharmacology, pharmacovigilance, regulatory affairs, data management, biostatistics, and consulting services across more than 20 therapeutic areas, including oncology, central nervous system disorders, rare diseases, and cell and gene therapies. The company operates through Clinical Services and Enabling Services segments, offering flexible delivery models such as full-service, functional service provider, and hybrid structures to streamline trial processes, optimize drug supply, and support patient dosing. Fortrea Holdings Inc. emphasizes innovation in decentralized trials, site partnerships, and technology integration to accelerate development timelines and enhance operational efficiency. Incorporated in 2023 and headquartered in Durham, North Carolina, it conducts operations in approximately 90 countries, partnering with sponsors to advance healthcare innovations from early-phase studies to post-approval support.
CEO Mr. Anshul Thakral · 14,000 employees · United States · https://www.fortrea.com